2nd Annual Complement-based Drug Development Summit 2018
In-Person Event
Nov 13 - 15, 2018
Boston, Massachusetts, USA
OVERVIEW
2nd Annual Complement-based Drug Development Summit 2018 is organized by Hanson Wade and will be held from Nov 13 - 15, 2018 at Hilton Boston Logan Airport, Boston, Massachusetts, United States of America.
Course Description:
"Optimize complex discovery, biomarker validation and clinical translation to develop complement inhibition for rare and common diseases"
With the only approved complement therapeutic, Soliris, on the market for over a decade, the industry is overflowing with companies in clinical translation in a race for the next approval. The 2nd Complement-based Drug Development Summit encapsulates this excitement and provides one platform for every leading complement company to network and learn in an effort to overcome common challenges including:
• Create Translatable Complement Assays: Explore the need for a standardized assay to minimize variation between labs and accurately determine clear and reliable clinical comparisons.
• Identify which Common Indication will Benefit Most: As the industry delves into targeting common disease indications, this meeting will explore which indication has the most potential for clinical success.
• Identify Novel Biomarkers to Improve Efficacy Assessments: Identify biomarkers that are driving disease and indicating complement activation to allow accurate measurements of efficacy and endpoints.
• The Role of Complement in the CNS: Understand the biology of complement in the CNS and explore which complexes can be targeted to treat neurological disorders.
Time: 08:00am to 17:00pm
Speakers:
Mark Ma, Senior Director, Bioanalytical and Biomarker Development, Alexion Research, Mingjun Huang, Senior Vice President and Head of Research, Achillion Pharmaceuticals, Anna Borodovsky, Associate Director, Alnylam Inc, Lukas Scheibler, Executive Vice President, Research and Translatable Medicine, Apellis Pharmaceuticals, Rajinder Singh, Senior Vice President of Research, ChemoCentryx, Mel Berger Senior Medical Director, Immunology RandD CSL Behring, Frank Baas, Chief Scientific Officer, Complement Pharma, Sharookh Kapadia, Sr. Scientist and Project Team Leader, Infectious Diseases, Genentech, Adam Rogers, Chief Executive Officer, Hemera Biosciences, Niels Riedemann, Chief Executive Officer, InflaRx, Michael McCaleb, Vice President, Clinical Development, Ionis Pharmaceuticals, Mike Ero, Chief Executive Officer, Machaon Diagnostics, Andrew Luster, Chief, Division of Rheumatology, Allergy and Immunology and Director, Center for Immunology and Inflammatory Diseases - Massachusetts General Hospital, Dimitrios Kapogiannis, Clinical Investigator, National Institute of Neurological Disorders and Stroke, Simon Read, Chief Scientific Officer, Ra Pharma, Barbara Klughammer, Senior Principal Scientist, Roche Pharma Research and Early Development, Dan Granoff, Clarox Endowed Chair and Director, Center for Immunobiology and Vaccine Development, UCSF Benioff Children’s Hospital Oakland Research Institute, Sanjay Ram, Professor of Medicine, University of Massachusetts Medical School.
Course Description:
"Optimize complex discovery, biomarker validation and clinical translation to develop complement inhibition for rare and common diseases"
With the only approved complement therapeutic, Soliris, on the market for over a decade, the industry is overflowing with companies in clinical translation in a race for the next approval. The 2nd Complement-based Drug Development Summit encapsulates this excitement and provides one platform for every leading complement company to network and learn in an effort to overcome common challenges including:
• Create Translatable Complement Assays: Explore the need for a standardized assay to minimize variation between labs and accurately determine clear and reliable clinical comparisons.
• Identify which Common Indication will Benefit Most: As the industry delves into targeting common disease indications, this meeting will explore which indication has the most potential for clinical success.
• Identify Novel Biomarkers to Improve Efficacy Assessments: Identify biomarkers that are driving disease and indicating complement activation to allow accurate measurements of efficacy and endpoints.
• The Role of Complement in the CNS: Understand the biology of complement in the CNS and explore which complexes can be targeted to treat neurological disorders.
Time: 08:00am to 17:00pm
Speakers:
Mark Ma, Senior Director, Bioanalytical and Biomarker Development, Alexion Research, Mingjun Huang, Senior Vice President and Head of Research, Achillion Pharmaceuticals, Anna Borodovsky, Associate Director, Alnylam Inc, Lukas Scheibler, Executive Vice President, Research and Translatable Medicine, Apellis Pharmaceuticals, Rajinder Singh, Senior Vice President of Research, ChemoCentryx, Mel Berger Senior Medical Director, Immunology RandD CSL Behring, Frank Baas, Chief Scientific Officer, Complement Pharma, Sharookh Kapadia, Sr. Scientist and Project Team Leader, Infectious Diseases, Genentech, Adam Rogers, Chief Executive Officer, Hemera Biosciences, Niels Riedemann, Chief Executive Officer, InflaRx, Michael McCaleb, Vice President, Clinical Development, Ionis Pharmaceuticals, Mike Ero, Chief Executive Officer, Machaon Diagnostics, Andrew Luster, Chief, Division of Rheumatology, Allergy and Immunology and Director, Center for Immunology and Inflammatory Diseases - Massachusetts General Hospital, Dimitrios Kapogiannis, Clinical Investigator, National Institute of Neurological Disorders and Stroke, Simon Read, Chief Scientific Officer, Ra Pharma, Barbara Klughammer, Senior Principal Scientist, Roche Pharma Research and Early Development, Dan Granoff, Clarox Endowed Chair and Director, Center for Immunobiology and Vaccine Development, UCSF Benioff Children’s Hospital Oakland Research Institute, Sanjay Ram, Professor of Medicine, University of Massachusetts Medical School.
KEY DATES
13 Nov, 2018
Event Start Date
15 Nov, 2018
Event End Date
SUGGESTED HOTELS
CONFERENCE VENUE
Hilton Boston Logan AirportQuick Links